ARTICLE | Clinical News
Esbriet pirfenidone: Phase III started
July 18, 2011 7:00 AM UTC
InterMune began the double-blind, placebo-controlled, international Phase III ASCEND trial to evaluate 2,403 mg/day Esbriet in about 500 patients. InterMune has rights to pirfenidone from Marnac in th...